Researchers released in the journal Diabetes Care their findings on a class of medication for type 2 diabetes, suggesting it may help treat older adults at risk of dementia.
The study focused on sodium-glucose cotransporter-2 (SGLT2) inhibitors. In their study, researchers found that SGLT2 inhibitors was associated with a 20 percent lower risk of dementia when compared to other inhibitors.
Common SGLT2 inhibitors include empagliflozin and dapagliflozin.
“Among 106,903 individuals, SGLT2 inhibitors compared with DPP-4 inhibitors were associated with lower risk of dementia over a mean follow-up of 2.80 years from cohort entry,” according to the study’s authors.
“SGLT2 inhibitors showed an association with lower dementia risk in older people with T2D. Randomized controlled trials are warranted.”
The study was published on December 12, 2022.
